Hepatitis C News and Research

Latest Hepatitis C News and Research

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

Idera Pharmaceuticals, Inc. today announced the presentation of preclinical data of its novel gene-silencing oligonucleotide technology including observations that demonstrate GSOs exert gene-silencing activity through a similar cellular pathway as siRNA.

25 May 2011

HIV & hepatitis fears for soldiers at Middle East hospital due to protocol lapse

Australian soldiers and contractors might have been exposed to blood-borne diseases such as hepatitis or HIV after staff at Defense’s main hospital unit in the Middle East failed to sterilize surgical equipment properly.

24 May 2011

Study offers hope for reducing incidence of AIDS with potential preventive vaccine

The HIV epidemic is the largest in the world and represents one of the most serious public health problems, according to data from the World Health Organization. Only 30% of the more than 10 million patients in need have the access to the antiretroviral treatment.

24 May 2011

Some providers fight for chance at federal health IT funding

IWatch news reports on this emerging issue while Modern Healthcare notes that a New Mexico Telehealth Project May Be National Modelrecent developments regarding health information technology.

24 May 2011

Novel hepatitis C-like virus discovered in dogs

In a study to be published online this week in the Proceedings of the National Academy of Sciences, researchers report the discovery of a novel hepatitis C-like virus in dogs. The identification and characterization of this virus gives scientists new insights into how hepatitis C in humans may have evolved and provides scientists renewed hope to develop a model system to study how it causes disease.

24 May 2011

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

The U.S. Food and Drug Administration today approved Incivek treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin.

24 May 2011

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present the Aethlon ADAPT™ system in a presentation at the C21 BioVentures™ Life Sciences Partnering Conference.

23 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Roche's new cobas TaqScreen MPX viral discriminatory test, v2.0 now available in Europe

Roche announced today that the cobas TaqScreen MPX Test, version 2.0 for use on the cobas s 201 system is now commercially available in Europe.

23 May 2011

Research roundup: Closing E.R.S; Predicting future health costs; Providing rural residents with specialized care

Factors Associated With The Closures Of Emergency Departments In The United States -- This study looks at the community, market and medical factors that led to an increase of urban hospital-based emergency department closures.

20 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced results from the ASPIRE phase 2b study that evaluates the addition of once daily TMC435 to pegylated interferon and ribavirin in patients with genotype 1 chronic hepatitis C whose prior treatment with pegylated-interferon (PegIFN) and ribavirin (RBV) was unsuccessful either because they relapsed, had a partial response or had a null response.

20 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States.

19 May 2011

Haiti presents plan to immunize 90 percent of newborns

Haiti has a plan to vaccinate 90 percent of newborns by 2015, according to PAHO, but "whether the plan works will depend on Haiti's ability to reverse decades of incompetent government and bad coordination among aid groups," as well as whether there will be funding, the New York Times reports.

18 May 2011

Gastroenterologists have limited knowledge of appropriate immunizations for IBD patients, study finds

Researchers from Boston University School of Medicine, along with clinicians from Boston Medical Center, have found gastroenterologist knowledge of the appropriate immunizations to recommend to the inflammatory bowel disease patient is limited.

17 May 2011

Benitec raises AU$8 million for gene silencing therapeutics

Benitec Ltd (ASX:BLT), a world leader in RNA-based gene silencing for human therapeutics, today announced its fully underwritten AU$8 million renounceable rights issue, incorporating an entitlement offer and a shortfall offer, had successfully closed oversubscribed.

17 May 2011

FDA nod for hepatitis C drug

Merck & Co have finally won the Food and Drugs Administration – FDA’S approval on Friday to sell a new drug considered a major advance against the liver-destroying hepatitis C virus. The drug brand named, Victrelis is expected to help transform treatment of the potentially fatal disease with higher cure rates and shorter courses of therapy for some patients. Merck shares rose 0.6 percent in after-hours trading to $37.33, up from their $37.08 close on the New York Stock Exchange. Approval of Victrelis was widely expected after a FDA advisory panel recommended the drug in an 18-0 vote in April.

17 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

Idera Pharmaceuticals' preclinical data on novel GSO technology presented at TIDES 2011

HIV & hepatitis fears for soldiers at Middle East hospital due to protocol lapse

Study offers hope for reducing incidence of AIDS with potential preventive vaccine

Some providers fight for chance at federal health IT funding

Novel hepatitis C-like virus discovered in dogs

Vertex Incivek receives FDA approval for treatment of chronic hepatitis C

Aethlon to introduce new adaptive dialysis-like affinity platform technology at C21 partnering conference

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Roche's new cobas TaqScreen MPX viral discriminatory test, v2.0 now available in Europe

Research roundup: Closing E.R.S; Predicting future health costs; Providing rural residents with specialized care

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Medivir reports positive results from ASPIRE TMC435 phase 2b study for genotype 1 chronic hepatitis C

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Abbott RealTime PCR assay for measuring HCV viral load receives FDA marketing approval

Haiti presents plan to immunize 90 percent of newborns

Gastroenterologists have limited knowledge of appropriate immunizations for IBD patients, study finds

Benitec raises AU$8 million for gene silencing therapeutics

FDA nod for hepatitis C drug

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in